Statistics
Publications
127
Citations
22.1K
H-Index
60
Active since
1982
Affiliations
Saul H. Rosenberg is an author at Abbott Fund specializing in pharmacology, oncology, and drug discovery.
Publications per year
1982–2024
127
127
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker et al. · Nature · 2005 · 3.4K citations
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · Cancer Research · 2008 · 2K citations · Full text
Medicine, Oncology, Pharmacology +16
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Loren Lasko, Clarissa G. Jakob, Rohinton Edalji et al. · Nature · 2017 · 858 citations · Full text
Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman et al. · The Lancet Oncology · 2010 · 853 citations · Full text
1–5 of 127